QuidelOrtho reported solid Q3 2025 results, showcasing organic sales growth of 5% and an adjusted EBITDA margin of 25%, reflecting strong performance across its diversified diagnostics portfolio.

• Organic sales growth of 5%, excluding COVID and the U.S. donor screening business, driven by strong demand in labs, immunohematology, and point-of-care sectors.
• Adjusted EBITDA increased to $177 million, with a margin improvement of 180 basis points year-over-year.
• Latin America led growth outside the U.S. with a 21% increase, while overall international revenue demonstrated strong momentum.
• Successful FDA clearance of the new VITROS high-sensitivity troponin assay, enhancing the cardiac testing portfolio and potential for reduced hospital admissions.
• Ongoing cost optimization initiatives have resulted in over $140 million in savings, setting the stage for sustainable mid- to high-20s EBITDA margins.